PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
10926928-0	2000	Inhibitory effects of MLDG-containing heterodimeric disintegrins reveal distinct structural requirements for interaction of the integrin alpha 9beta 1 with VCAM-1, tenascin-C, and osteopontin.	mldg	22-26	vascular cell adhesion molecule 1	Homo sapiens	156-162
10926928-0	2000	Inhibitory effects of MLDG-containing heterodimeric disintegrins reveal distinct structural requirements for interaction of the integrin alpha 9beta 1 with VCAM-1, tenascin-C, and osteopontin.	mldg	22-26	tenascin C	Homo sapiens	164-174
10926928-0	2000	Inhibitory effects of MLDG-containing heterodimeric disintegrins reveal distinct structural requirements for interaction of the integrin alpha 9beta 1 with VCAM-1, tenascin-C, and osteopontin.	mldg	22-26	secreted phosphoprotein 1	Homo sapiens	180-191
10212222-8	1999	MLDG partially inhibited adhesion of K562 cells to fibronectin (5-10 mM) in contrast to RGDS peptide (IC50 = 3 mM), inhibiting completely at 10 mM.	mldg	0-4	fibronectin 1	Homo sapiens	51-62
24648940-7	2013	In addition, immunohistochemistry showed that although cWPROL and the mixture of lidocaine, dexamethasone and gentamycin (mLDG) induced levels of EGF and TGF-beta1 expression, there were differences between the two types of intervention.	mldg	122-126	epidermal growth factor like 1	Rattus norvegicus	146-149
24648940-7	2013	In addition, immunohistochemistry showed that although cWPROL and the mixture of lidocaine, dexamethasone and gentamycin (mLDG) induced levels of EGF and TGF-beta1 expression, there were differences between the two types of intervention.	mldg	122-126	transforming growth factor, beta 1	Rattus norvegicus	154-163